

Skin Disease-Oriented Team

Clinical Research Treatment Flowchart

First Line, Resectable

SWOG 2015

1cm v 2cm margin
 CRC: N. Arechiga
 Accrual: 6/30

**First Line, Stage 3
 Neoadjuvant + Adjuvant**

EA6194

TLR9 agonist+Pembro + Sx vs Pembro + Sx

CRC: E. Palmer-Torrison
 Accrual: 3/5

**First Line, Metastatic or unresectable
 without previous CPI**

EA6141

(III or IV)

Ipi + Nivo + sargramostin **vs.** Ipi + Nivo

CRC: B. Huynh
 Accrual: 4/7

UCI 22-101

(III or IV)

Nivo + Rela IV vs SubQ

CRC: N. Arechiga
 Accrual: 4/12

Second Line

UCI 22-213

E7386 + Pembro +/- Lenvatinib
 CRC: N. Arechiga
 Accrual: 0/7

Open

Low Accrual

Pending
 Activation
 or
 Suspended

HER2 + /
ERBB2
amp

UCI 20-67

DF1001 (HER2 NK-
engager)
PI: Valerin
CRC: M. Nguyen
Accrual: 18/20

UCI 21-40

*(Locally Advanced or
Metastatic Solid
Tumors)*

DF6002 as a
Monotherapy and
in Combination w/
nivo

PI: Valerin
CRC: B. Huynh
Accrual: 4/6
Waitlist only

UCI 20-110

TAK-981 + Pembro
(sumoylation inhibitor)

PI: Tewari
CRC: N. Patel
Accrual: 2/5

**UCI 22-87
(RMC-6236)**

PI: Ou
Mechanism: TKI
Coordinator: Oliver
Quines
Accrual: 12/20
RAS Mutation

UCI 23-197

DF6215 (IL-2)
PI: Valerin
CRC: TBD
Accrual: 0/5

Open

Low Accrual

Pending
Activation
or
Suspended

Non-treatment Trials

UCI 19-135

DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)

CRC: Anastasiia R.

Accrual: 66/90

Open

Low Accrual

Pending
Activation
or
Suspended

Recurrent

ETCTN 10592
M1774 +/- avelumab

CRC: N. Arechiga
Accrual: 0/6

Open

Low Accrual

Pending
Activation
or
Suspended

First Line

Broad Phase 1 trials

UCI 22-42

TransCon Toll like receptor
(TLR) 7/8 agonist
Coord: Nirali Patel
Accrual: 0/5

UCI 22-87

(RMC-6236)
Mechanism: TKI
Coordinator: Oliver
Quines
Accrual: 12/20
RAS Mutation

Open

Low Accrual

Pending
Activation or
Suspended

Closed